Jeito Capital to sell EyeBiotech to Merck & Co for $3bn

EyeBiotech is a clinical-stage ophthalmology biotechnology company.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this